Evidence map›Paper›PMID 35871543›Full record

ArticleProtein engineering, design & selection : PEDS2022

Affinity maturation of TCR-like antibodies using phage display guided by structural modeling.

Rahel Frick, Lene S Høydahl, Ina Hodnebrug, Erik S Vik, Bjørn Dalhus, Ludvig M Sollid, Jeffrey J Gray, Inger Sandlie, Geir Åge Løset

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rahel FrickCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.ORCID 0000-0002-3469-5686
Lene S HøydahlCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.ORCID 0000-0001-6070-1413
Ina HodnebrugCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.
Erik S VikNextera AS, Gaustadalléen 21, 0349 Oslo, Norway.
Bjørn DalhusDepartment for Medical Biochemistry, Institute for Clinical Medicine, University of Oslo, Sognsvannsveien 20, 0372 Oslo, Norway.
Ludvig M SollidCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.
Jeffrey J GrayProgram in Molecular Biophysics, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
Inger SandlieCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.
Geir Åge LøsetCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.ORCID 0000-0002-5257-8571

Funding

Prediction of the Structure of Therapeutic Antibodies with their AntigensR01GM078221 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GRAY, JEFFREY J · 2006 to 2020
$4.0M
NIGMS NIH HHS R01 GM078221
6 · The paper itself

Abstract

TCR-like antibodies represent a unique type of engineered antibodies with specificity toward pHLA, a ligand normally restricted to the sensitive recognition by T cells. Here, we report a phage display-based sequential development path of such antibodies. The strategy goes from initial lead identification through in silico informed CDR engineering in combination with framework engineering for affinity and thermostability optimization, respectively. The strategy allowed the identification of HLA-DQ2.5 gluten peptide-specific TCR-like antibodies with low picomolar affinity. Our method outlines an efficient and general method for development of this promising class of antibodies, which should facilitate their utility including translation to human therapy.

Indexed as

AntibodiesBacteriophagesHumansPeptidesReceptors, Antigen, T-CellT-LymphocytesAntibodiesPeptidesReceptors, Antigen, T-Cellantibodyceliac diseasephage display

Identifiers

PMID35871543
PMCPMC9536190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.